$NBIX
NEUROCRINE BIOSCIENCES INC

2017 Q4 Form 10-K Financial Statement

#000119312518042794 Filed on February 13, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017
Revenue $94.52M $60.77M $161.6M
YoY Change 977.51%
Cost Of Revenue $800.0K $433.0K $1.254M
YoY Change
Gross Profit $93.80M $60.34M $160.4M
YoY Change 969.15%
Gross Profit Margin 99.24% 99.29% 99.22%
Selling, General & Admin $56.30M $43.87M $169.9M
YoY Change 137.55% 150.79% 149.56%
% of Gross Profit 60.02% 72.71% 105.94%
Research & Development $25.60M $22.46M $121.8M
YoY Change 13.27% 7.26% 29.2%
% of Gross Profit 27.29% 37.23% 75.97%
Depreciation & Amortization $700.0K $600.0K $2.400M
YoY Change 40.0% 50.0% 60.0%
% of Gross Profit 0.75% 0.99% 1.5%
Operating Expenses $82.68M $66.77M $293.0M
YoY Change 78.77% 73.71% 80.44%
Operating Profit $11.12M -$5.995M -$131.4M
YoY Change -84.4% -10.86%
Interest Expense -$5.100M $7.337M $19.52M
YoY Change -828.57%
% of Operating Profit -45.88%
Other Income/Expense, Net $200.0K -$5.130M -$11.18M
YoY Change -77.78% -431.18% -277.98%
Pretax Income $6.900M -$11.10M -$142.5M
YoY Change -115.44% -69.92% 1.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings $6.894M -$11.13M -$142.5M
YoY Change -115.44% -69.84% 1.03%
Net Earnings / Revenue 7.29% -18.31% -88.19%
Basic Earnings Per Share $0.08 -$0.13 -$1.62
Diluted Earnings Per Share $0.07 -$0.13 -$1.62
COMMON SHARES
Basic Shares Outstanding 88.67M 88.33M 88.09M
Diluted Shares Outstanding 92.66M 88.33M 88.09M

Balance Sheet

Concept 2017 Q4 2017 Q3 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $515.9M $511.0M $515.9M
YoY Change 67.84% 44.76% 67.83%
Cash & Equivalents $254.7M $267.8M $254.7M
Short-Term Investments $261.2M $243.2M $261.2M
Other Short-Term Assets $6.839M $7.407M $7.900M
YoY Change 121.18% 52.75% 154.84%
Inventory $1.024M $242.0K
Prepaid Expenses
Receivables $31.13M $29.82M $31.10M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $554.9M $548.5M $554.9M
YoY Change 78.75% 53.25% 78.77%
LONG-TERM ASSETS
Property, Plant & Equipment $10.81M $9.140M $10.80M
YoY Change 72.4% 47.9% 71.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $247.4M $210.3M $247.4M
YoY Change 468.74% 596.36% 468.74%
Other Assets $4.500M $4.600M $4.500M
YoY Change -8.16% -6.12% -8.16%
Total Long-Term Assets $262.7M $224.0M $262.7M
YoY Change 380.7% 442.79% 380.26%
TOTAL ASSETS
Total Short-Term Assets $554.9M $548.5M $554.9M
Total Long-Term Assets $262.7M $224.0M $262.7M
Total Assets $817.6M $772.5M $817.6M
YoY Change 123.94% 93.53% 123.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.648M $37.30M $5.600M
YoY Change 11.07% 2069.87% 9.8%
Accrued Expenses $47.90M
YoY Change 127.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.43M $38.14M $54.40M
YoY Change 78.95% 43.03% 78.95%
LONG-TERM LIABILITIES
Long-Term Debt $369.6M $365.1M $369.6M
YoY Change
Other Long-Term Liabilities $0.00 $113.0K $21.40M
YoY Change -100.0% 0.0% 8.08%
Total Long-Term Liabilities $0.00 $113.0K $391.0M
YoY Change -100.0% 0.0% 1874.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.43M $38.14M $54.40M
Total Long-Term Liabilities $0.00 $113.0K $391.0M
Total Liabilities $445.5M $425.0M $445.5M
YoY Change 787.2% 794.51% 787.45%
SHAREHOLDERS EQUITY
Retained Earnings -$1.199B -$1.206B
YoY Change 13.49% 19.19%
Common Stock $1.573B $1.554B
YoY Change 14.68% 13.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $372.2M $347.5M $372.1M
YoY Change
Total Liabilities & Shareholders Equity $817.6M $772.5M $817.6M
YoY Change 123.94% 93.53% 123.94%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017
OPERATING ACTIVITIES
Net Income $6.894M -$11.13M -$142.5M
YoY Change -115.44% -69.84% 1.03%
Depreciation, Depletion And Amortization $700.0K $600.0K $2.400M
YoY Change 40.0% 50.0% 60.0%
Cash From Operating Activities $40.60M -$9.300M -$94.33M
YoY Change -228.48% -70.1% -11.16%
INVESTING ACTIVITIES
Capital Expenditures -$2.300M -$2.800M $6.940M
YoY Change 666.67% 250.0% 68.94%
Acquisitions
YoY Change
Other Investing Activities -$57.30M -$32.60M -$244.3M
YoY Change -469.68% -174.09% -308.63%
Cash From Investing Activities -$59.70M -$35.40M -$251.3M
YoY Change -492.76% -181.94% -322.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.87M
YoY Change 480.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.600M 3.000M 516.6M
YoY Change 5500.0% 130.77% 21516.99%
NET CHANGE
Cash From Operating Activities 40.60M -9.300M -94.33M
Cash From Investing Activities -59.70M -35.40M -251.3M
Cash From Financing Activities 5.600M 3.000M 516.6M
Net Change In Cash -13.50M -41.70M 171.1M
YoY Change -17.18% -411.19% 1766.67%
FREE CASH FLOW
Cash From Operating Activities $40.60M -$9.300M -$94.33M
Capital Expenditures -$2.300M -$2.800M $6.940M
Free Cash Flow $42.90M -$6.500M -$101.3M
YoY Change -237.06% -78.55% -8.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89273537 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
3407988476
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5750000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.31
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
208699000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23854000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31014000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5507000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.63
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
424454000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
33074000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74195000
CY2015Q4 nbix Cease Use Liability
CeaseUseLiability
1983000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86883300 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86883300 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6112000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1056324000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
113000
CY2016Q4 us-gaap Liabilities
Liabilities
50209000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365086000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9559000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
26182000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-318000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5085000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30414000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
463500000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
470000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
310442000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
241956000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
314877000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
87000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1371432000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25950000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
34112000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1462000
CY2016Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5995000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
324000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4400000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
17400000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4300000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3092000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6271000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4883000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
224083000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
251100000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83267000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
309100000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
463500000
CY2016Q4 us-gaap Investments
Investments
267600000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
43490000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
321000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction
DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction
3800000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
400000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
38800000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
32221000
CY2016Q4 us-gaap Assets
Assets
365086000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
9144000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
267573000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4800000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
463500000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5543000
CY2016Q4 nbix Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
80200000
CY2016Q4 nbix Deferred Tax Liabilities Convertible Debt
DeferredTaxLiabilitiesConvertibleDebt
0
CY2016Q4 nbix Deferred Tax Assets Lease Termination Charges
DeferredTaxAssetsLeaseTerminationCharges
300000
CY2016Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3526000
CY2016Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
7372000
CY2016Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
617000
CY2016Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
236000
CY2016Q4 nbix Cease Use Liability
CeaseUseLiability
853000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88793903 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6300000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88793903 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4200000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.22
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6356000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.83
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
30700000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1198866000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
104880000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
7589000
CY2017Q4 us-gaap Liabilities
Liabilities
445453000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
817591000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24901000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31800000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
53520000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1850000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5648000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
372138000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Next Rolling Twelve Months
OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths
7368000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
8079000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2017Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
517500000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
89000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1572765000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
500000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0
CY2017Q4 us-gaap Assets Current
AssetsCurrent
554919000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
460252000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
74000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
1851000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27580000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37403000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
113000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
7844000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3135000
CY2017Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
369618000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
8800000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18172000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
74000000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54426000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
330900000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8000000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
14600000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2800000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7863000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10811000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4500000
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
4700000
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
261217000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
495818000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254712000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
238500000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
330900000
CY2017Q4 us-gaap Investments
Investments
508600000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
309900000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31127000
CY2017Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
247361000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1777000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction
DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction
2100000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
47500000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38391000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
234900000
CY2017Q4 us-gaap Assets
Assets
817591000
CY2017Q4 nbix Number Of Subsidiaries Held
NumberOfSubsidiariesHeld
2 Subsidiary
CY2017Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
731000
CY2017Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
8043000
CY2017Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
0
CY2017Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
62000
CY2017Q4 nbix Cease Use Liability
CeaseUseLiability
62000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
35566000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
508578000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
138230000
CY2017Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
9652000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1700000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
362700000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 nbix Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4799000
CY2017Q4 nbix Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
47500000
CY2017Q4 nbix Deferred Tax Liabilities Convertible Debt
DeferredTaxLiabilitiesConvertibleDebt
31300000
CY2017Q4 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2017Q4 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
3000000
CY2017Q4 nbix Deferred Tax Assets Lease Termination Charges
DeferredTaxAssetsLeaseTerminationCharges
0
CY2017Q4 nbix Potential Milestone Payments
PotentialMilestonePayments
132000000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270700000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37997000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.01
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84496000 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84496000 shares
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
46.08
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.21
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
87000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.24
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1315000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1159000 shares
CY2015 us-gaap Revenues
Revenues
19769000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1934000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
1928000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10231000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6636000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6304000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
270687000
CY2015 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
3300000
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
449052000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-6032000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-700000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-94202000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-88929000
CY2015 us-gaap Interest Paid
InterestPaid
0
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89629000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28392000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2584000
CY2015 us-gaap Licenses Revenue
LicensesRevenue
19769000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6638000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5273000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-40000
CY2015 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
489000
CY2015 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
3334000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28392000
CY2015 us-gaap Depreciation
Depreciation
1000000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
10773000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-16000
CY2015 us-gaap Interest Expense
InterestExpense
0
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-195814000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
276992000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
28392000
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1009000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-31126000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
172000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
201000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3291000
CY2015 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
9000
CY2015 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
5594000
CY2015 nbix Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
0
CY2015 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
3325000
CY2015 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
255123000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32480000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
53000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-39000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
6000000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
276992000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81491000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
43600000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
43181000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15029000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9841000
CY2015 us-gaap Operating Expenses
OperatingExpenses
113971000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6300000
CY2015 nbix Income Tax Reconciliation Uncertain Tax Positions
IncomeTaxReconciliationUncertainTaxPositions
5940000
CY2015 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-85000
CY2015 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-610000
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.60 pure
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-94331000
CY2017 us-gaap Licenses Revenue
LicensesRevenue
45000000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
8352000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.41
CY2017 dei Trading Symbol
TradingSymbol
NBIX
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88089000 shares
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88089000 shares
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk.</i></b>&#xA0;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivables. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that maintain safety and liquidity.</font></p> </div>
CY2017 us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13864000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
43.05
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
46.55
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
210000 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.11
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-142542000
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1353000 shares
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates.</i></b>&#xA0;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</font></p> </div>
CY2017 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2017 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Revenue Recognition.</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Product Sales, Net.</i></b>&#xA0;The Company&#x2019;s net product sales consist of U.S. sales of INGREZZA and are recognized when (i)&#xA0;persuasive evidence of an arrangement exists, (ii)&#xA0;delivery has occurred and title to the product and associated risk of loss has passed to the customer, (iii)&#xA0;the price is fixed or determinable, and (iv)&#xA0;collectability is reasonably assured.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">INGREZZA was approved by the FDA on April&#xA0;11, 2017 and the Company commenced shipments of INGREZZA to select pharmacies (SPs) and a select distributor (SD) in late April 2017. The&#xA0;SPs&#xA0;dispense&#xA0;product to a patient based on the fulfillment&#xA0;of&#xA0;a prescription and&#xA0;the SD&#xA0;sells&#xA0;product to government facilities, long-term care pharmacies or&#xA0;in-patient hospital&#xA0;pharmacies. The Company&#x2019;s agreements with SPs and SDs provide for transfer of title to the product at the time the product is delivered to the SP or SD. In addition, except for limited circumstances, the SPs and SDs have no right of product return to the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company has determined it can reasonably estimate its sales allowances at the time title and risk of loss transfers to the SP or SD. Therefore, the Company records revenue when the product is delivered to the SPs or SD, which is an approach frequently referred to as the &#x201C;sell-in&#x201D; revenue&#xA0;recognition&#xA0;model.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company recognizes revenue from product sales net of the following allowances:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Distribution Fees:</i>&#xA0;Distribution fees include fees paid to the SPs and SD for data, prompt payment discounts and other off-invoice discounts. Distribution fees are recorded as an offset to gross revenue based on contractual terms at the time revenue from the sale is recognized.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Government Rebates:</i>&#xA0;Government rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and result from contractual agreements with, or statutory requirements pertaining to, Medicaid and Medicare benefit providers. The allowance for rebates is based on statutory discount rates, expected utilization and expected trends in net reimbursement. Expected utilization of rebates is based on prescription level detail provided by the SPs that includes insurer amounts for each prescription filled during the period as well as the limited amount of product that is in the SPs warehouse at period end.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Chargebacks:</i>&#xA0;Chargebacks are discounts that relate to contracts with government and other entities purchasing from the SD at a discounted price. The SD charges back to the Company the difference between the price initially paid by the SD and the discounted price paid to the SD by these entities. Chargebacks are recorded as an offset to gross revenue at the time revenue from the product sale is recognized based on known and expected SD sales to these entities.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Co-Payment Assistance:</i>&#xA0;The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is recorded as an offset to gross revenue at the time revenue from the product sale is recognized based on expected and actual program participation. Expected program participation is based on prescription level detail provided by the SPs that includes copay amounts for each prescription filled during the period as well as the limited amount of product that is in the SPs warehouse at period end.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Product Returns:</i>&#xA0;The Company offers the SPs and SD limited product return rights for damages and shipment errors provided it is within a very limited period after the original shipping date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient or for drug expiration. The Company receives real-time shipping reports and inventory reports from the SPs and SD and has the ability to control the amount of product that is sold to the SPs and SD. It is also able to make a reasonable estimate of potential product returns due to the limited time-frame allowed for the SPs and SD to process returns due to shipment error or damaged product.</font></p> </div>
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1807000 shares
CY2017 us-gaap Revenues
Revenues
161626000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6940000
CY2017 us-gaap Investment Income Net
InvestmentIncomeNet
6238000
CY2017 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2017 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
144948000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1756000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
116626000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1532000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-131361000
CY2017 us-gaap Interest Paid
InterestPaid
6242000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1024000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
31127000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-144074000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42522000
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3747000
CY2017 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2104000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42522000
CY2017 us-gaap Depreciation
Depreciation
2400000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
154415000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1100000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2400000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-49889000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
433000
CY2017 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
2100000
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
583408000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1203000
CY2017 us-gaap Interest Expense
InterestExpense
19523000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-250870000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13865000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
42522000
CY2017 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10937000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
28464000
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1433000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11181000
CY2017 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-383000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-19589000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
502781000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
339088000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
169906000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-956000
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5900000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
516646000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
121827000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
61400000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
848000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
171445000
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1254000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4013000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-79966000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
27338000
CY2017 us-gaap Operating Expenses
OperatingExpenses
292987000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13900000
CY2017 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
7000
CY2016 us-gaap Investment Income Net
InvestmentIncomeNet
2838000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3520000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
341000 shares
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1077000 shares
CY2016 us-gaap Revenues
Revenues
15000000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4108000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
659000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-147372000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-141090000
CY2016 us-gaap Interest Paid
InterestPaid
0
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-140431000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28464000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2211000
CY2016 us-gaap Licenses Revenue
LicensesRevenue
15000000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6511000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
260000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2390000
CY2016 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
3400000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
298776000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6282000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
92000
CY2016 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1791000
CY2016 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
3431000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28464000
CY2016 us-gaap Depreciation
Depreciation
1500000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-294000
CY2016 us-gaap Interest Expense
InterestExpense
0
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
112863000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2390000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2017 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
2998000
CY2017 nbix Operating Lease Expiration Year
OperatingLeaseExpirationYear
2029
CY2017 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2124000
CY2017 nbix Lease Expiration Year
LeaseExpirationYear
2029
CY2017 nbix Income Tax Reconciliation Uncertain Tax Positions
IncomeTaxReconciliationUncertainTaxPositions
2756000
CY2017 nbix Percentage Of Uncertain Tax Positions Likelihood Of Being Sustained
PercentageOfUncertainTaxPositionsLikelihoodOfBeingSustained
0.50 pure
CY2017 nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
CY2017 nbix Number Of Collaboration Agreements
NumberOfCollaborationAgreements
2 Agreement
CY2017 nbix Subleased Agreement Area
SubleasedAgreementArea
16000 sqft
CY2017 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
247000
CY2017 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-544000
CY2017 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-247000
CY2017 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-544000
CY2017 nbix Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
2163000
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-106181000
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.60
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86713000 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86713000 shares
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
34.35
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
40.19
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
131000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.49
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86713000 shares
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1453000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-49383000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-321000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-5077000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
415826000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
68081000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
211000
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-108000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
6000000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2390000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
94291000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13200000
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9072000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
53414000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4398000
CY2016 us-gaap Operating Expenses
OperatingExpenses
162372000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2400000
CY2016 nbix Other Nonoperating Gain Loss On Disposition Of Assets
OtherNonoperatingGainLossOnDispositionOfAssets
8000
CY2016 nbix Income Tax Reconciliation Expiration Of Tax Credits
IncomeTaxReconciliationExpirationOfTaxCredits
6708000
CY2016 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
3423000
CY2016 nbix Income Tax Reconciliation Uncertain Tax Positions
IncomeTaxReconciliationUncertainTaxPositions
957000
CY2016 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
300000
CY2016 nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
-584000
CY2016 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-300000
CY2016 nbix Change In Estimate On Cease Use Liability
ChangeInEstimateOnCeaseUseLiability
-830000
CY2016 nbix Income Tax Reconciliation Nondeductible Expense Officer Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseOfficerCompensationCost
0
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87283000 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87283000 shares
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-78326000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
79932000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86497000 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q1 us-gaap Revenues
Revenues
15000000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-19264000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
35857000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86694000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2016Q2 us-gaap Revenues
Revenues
0
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-40280000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
41828000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88063000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88063000 shares
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2017Q2 us-gaap Revenues
Revenues
6335000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-59985000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
63603000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86784000 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2016Q3 us-gaap Revenues
Revenues
0
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-36887000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
38436000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88325000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88325000 shares
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2017Q3 us-gaap Revenues
Revenues
60774000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-11125000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
66769000
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86874000 shares
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2016Q4 us-gaap Revenues
Revenues
0
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-44659000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
46251000
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92659000 shares
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88665000 shares
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2017Q4 us-gaap Revenues
Revenues
94517000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
6894000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
82683000

Files In Submission

Name View Source Status
0001193125-18-042794-index-headers.html Edgar Link pending
0001193125-18-042794-index.html Edgar Link pending
0001193125-18-042794.txt Edgar Link pending
0001193125-18-042794-xbrl.zip Edgar Link pending
d520757d10k.htm Edgar Link pending
d520757dex1017.htm Edgar Link pending
d520757dex1026.htm Edgar Link pending
d520757dex211.htm Edgar Link pending
d520757dex231.htm Edgar Link pending
d520757dex31.htm Edgar Link pending
d520757dex311.htm Edgar Link pending
d520757dex312.htm Edgar Link pending
d520757dex32.htm Edgar Link pending
d520757dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g520757g14l22.jpg Edgar Link pending
g520757g84z22.jpg Edgar Link pending
g520757g91r74.jpg Edgar Link pending
g520757g96o22.jpg Edgar Link pending
nbix-20171231.xml Edgar Link completed
nbix-20171231.xsd Edgar Link pending
nbix-20171231_cal.xml Edgar Link unprocessable
nbix-20171231_def.xml Edgar Link unprocessable
nbix-20171231_lab.xml Edgar Link unprocessable
nbix-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending